Unigene Laboratories is a biopharmaceutical company, engaged in the research and development of peptides for medical purposes. The company was founded in 1980 and is located in New Jersey. The company's primary focus is on the development of calcitonin and related peptides for the treatment of osteoporosis. The company has licensed worldwide rights to its oral parathyroid hormone ("PTH") to GlaxoSmithKline.

PropertyValue
dbpedia-owl:Company/industry
dbpedia-owl:Organisation/foundationDate
  • 1980-01-01 00:00:00 (xsd:date)
dbpedia-owl:Organisation/keyPersonPosition
  • James Gilligan, vice president, product development
  • Warren Levy, president & CEO
dbpedia-owl:Organisation/numberOfEmployees
  • 85 (xsd:integer)
dbpedia-owl:Organisation/type
dbpedia-owl:foundationDate
  • 1980-01-01 00:00:00 (xsd:date)
dbpedia-owl:industry
dbpedia-owl:keyPersonPosition
  • James Gilligan, vice president, product development
  • Warren Levy, president & CEO
dbpedia-owl:numberOfEmployees
  • 85 (xsd:integer)
dbpedia-owl:type
dbpprop:abstract
  • Unigene Laboratories is a biopharmaceutical company, engaged in the research and development of peptides for medical purposes. The company was founded in 1980 and is located in New Jersey. The company's primary focus is on the development of calcitonin and related peptides for the treatment of osteoporosis. The company has licensed worldwide rights to its oral parathyroid hormone ("PTH") to GlaxoSmithKline.
dbpprop:companyName
  • Unigene Laboratories
dbpprop:companyType
dbpprop:foundation
  • 1980 (xsd:integer)
dbpprop:hasPhotoCollection
dbpprop:homepage
dbpprop:industry
dbpprop:keyPeople
  • Warren Levy, president & CEO James Gilligan, vice president, product development
dbpprop:numEmployees
  • 85 (xsd:integer)
dbpprop:reference
dbpprop:wikiPageUsesTemplate
dbpprop:wordnet_type
rdf:type
rdfs:comment
  • Unigene Laboratories is a biopharmaceutical company, engaged in the research and development of peptides for medical purposes. The company was founded in 1980 and is located in New Jersey. The company's primary focus is on the development of calcitonin and related peptides for the treatment of osteoporosis. The company has licensed worldwide rights to its oral parathyroid hormone ("PTH") to GlaxoSmithKline.
rdfs:label
  • Unigene Laboratories
owl:sameAs
skos:subject
foaf:homepage
foaf:name
  • Unigene Laboratories
foaf:page
is dbpprop:disambiguates of
is owl:sameAs of